Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.Eva Ciruelos, Aleix Prat, Tomás Pascual et al.|Journal of Clinical Oncology|2024Cited by 8
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Marion van Mackelenbergh, Eva Ciruelos et al.|Nature Medicine|2024Cited by 8
Abstract P2-01-16: Pharmacogenomic variants and risk of adverse events in breast cancer patients treated with Trastuzumab-deruxtecan: results from the PROCURE projectRodrigo Sánchez-Bayona, Cristina Rodríguez‐Antona, Javier de Nicolás‐Hernández et al.|Clinical Cancer Research|2025Cited by 3
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast CancerEsther Sanfeliu, Aleix Prat, Javier Cortés et al.|Clinical Cancer Research|2025Cited by 3
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA TrialEva Ciruelos, Aleix Prat, Tomás Pascual et al.|Clinical Cancer Research|2025Cited by 0